You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Chimeric Antigen Receptor

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Neuroblastoma Trial (GD2 CAR T cells)

Not yet recruiting
  • Neuroblastoma
  • GD2 CAR T cells
  • (no location specified)
Aug 5, 2023

CAR-T Cell Induced Cardiac Dysfunction: A Prospective Study

Not yet recruiting
  • Lymphoma
  • Chimeric Antigen Receptor
  • (no location specified)
Oct 24, 2023

19 and 22+ B Cell Hematologic Tumors Trial in Wuhan (Autologous CD19/CD22 Chimeric Antigen Receptor T-cells)

Recruiting
  • 19 and 22+ B Cell Hematologic Tumors
  • 19 and 20+ B Cell Hematologic Tumors
  • Autologous CD19/CD22/CD20 Chimeric Antigen Receptor T-cells
  • Wuhan, Hubei, China
    Tongji Hospital
Jan 11, 2023

Kidney Transplant, Kidney Failure, Highly Sensitized Trial in Boston, New York, Philadelphia (Cyclophosphamide, CART-BCMA,

Not yet recruiting
  • Kidney Transplant
  • +2 more
  • Boston, Massachusetts
  • +2 more
Sep 20, 2023

Advanced Sarcoma Trial (NKG2D-CAR memory T cell)

Not yet recruiting
  • Advanced Sarcoma
  • NKG2D-CAR memory T cell
  • (no location specified)
Oct 17, 2023

Multiple Myeloma Trial in Houston (Fully human BCMA chimeric antigen receptor autologous T cell injection (CT103A))

Not yet recruiting
  • Multiple Myeloma
  • Fully human BCMA chimeric antigen receptor autologous T cell injection (CT103A)
  • Houston, Texas
    The University of Texas MD Anderson Cancer Center
Jan 13, 2023

Solid Tumor Trial (HER2-E-CART cells)

Not yet recruiting
  • Solid Tumor
  • HER2-E-CART cells
  • (no location specified)
Feb 16, 2023

Study of Participants Who ReceivedAllogeneic CAR T-Cell Product

Recruiting
  • Participants Who Received an Allogeneic Chimeric Antigen Receptor T-Cell Product (PBCAR) in a Precision BioSciences, Inc., Clinical Study
    • Culver City, California
      Science 37, Inc.
    Apr 10, 2023

    Neuroendocrine Tumor (NET), Colorectal Cancer (CRC) Trial (CHM-2101 CAR-T cells)

    Not yet recruiting
    • Neuroendocrine Tumor (NET)
    • Colorectal Cancer (CRC)
    • CHM-2101 CAR-T cells
    • (no location specified)
    Sep 20, 2023

    Gastric Cancer, Colon Cancer, Rectal Cancer Trial in Taiyuan (CEA-targeted CAR-T cells)

    Recruiting
    • Gastric Cancer
    • +6 more
    • CEA-targeted CAR-T cells
    • Taiyuan, Shanxi, China
    • +1 more
    Aug 24, 2023

    Small Cell Lung Cancer Extensive Stage, Large Cell Neuroendocrine Carcinoma of the Lung Trial (LB2102)

    Not yet recruiting
    • Small Cell Lung Cancer Extensive Stage
    • Large Cell Neuroendocrine Carcinoma of the Lung
    • LB2102
    • (no location specified)
    Jan 10, 2023

    Follicular Lymphoma Trial (Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine phosphate)

    Not yet recruiting
    • Follicular Lymphoma
    • Axicabtagene Ciloleucel
    • +5 more
    • (no location specified)
    Sep 21, 2023

    Colorectal Cancer, Esophagus Cancer, Gastric Cancer Trial in Hangzhou (CEA-targeted CAR-T cells)

    Recruiting
    • Colorectal Cancer
    • +6 more
    • CEA-targeted CAR-T cells
    • Hangzhou, Zhejiang, China
    • +1 more
    Sep 18, 2023

    Gastric Cancer, Colon Cancer, Rectal Cancer Trial in Wuhu (CEA-targeted CAR-T cells)

    Recruiting
    • Gastric Cancer
    • +7 more
    • CEA-targeted CAR-T cells
    • Wuhu, Anhui, China
      The First Affiliated Hospital of Wannan Medical College
    Nov 9, 2023

    Lupus Nephritis, Lupus Nephritis - World Health Organization (WHO) Class III, Lupus Nephritis - WHO Class IV Trial in Denver,

    Recruiting
    • Lupus Nephritis
    • +2 more
    • KYV-101 anti-CD19 CAR-T cell therapy
    • Standard lymphodepletion regimen
    • Denver, Colorado
    • +1 more
    Jul 7, 2023

    Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive Trial in Palo Alto

    Not yet recruiting
    • Multiple Sclerosis
    • +2 more
    • KYV-101 anti-CD19 CAR-T cell therapy
    • Standard lymphodepletion regimen
    • Palo Alto, California
      Stanford Multiple Sclerosis Center
    Nov 13, 2023

    Acute Myeloid Leukemia Trial in Kunming (Anti-CLL1 CART cells)

    Recruiting
    • Acute Myeloid Leukemia
    • Anti-CLL1 CART cells
    • Kunming, Yunnan, China
      No.212 Daguan Road, Xishan District
    Nov 23, 2022

    Refractory Multiple Myeloma, Relapsed Multiple Myeloma Trial in San Francisco (Manufactured Anti-BCMA CAR-T cells, Fludarabine,

    Recruiting
    • Refractory Multiple Myeloma
    • Relapsed Multiple Myeloma
    • Manufactured Anti-BCMA CAR-T cells
    • +2 more
    • San Francisco, California
      University of California, San Francisco
    Jan 6, 2023

    Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma Trial in Tianjin (CD19-targeted Chimeric Antigen Receptor(CAR) T Cells)

    Recruiting
    • Lymphoma, Non-Hodgkin
    • Diffuse Large B Cell Lymphoma
    • CD19-targeted Chimeric Antigen Receptor(CAR) T Cells
    • Tianjin, Tianjin, China
      Tianjin Cancer Hospital
    Nov 19, 2023

    Immunotherapy, Multiple Myeloma Trial in Zhengzhou (Chimeric Antigen Receptor NK Cell Injection Targeting BCMA (BCMA CAR-NK))

    Recruiting
    • Immunotherapy
    • Multiple Myeloma
    • Chimeric Antigen Receptor NK Cell Injection Targeting BCMA (BCMA CAR-NK)
    • Zhengzhou, Henan, China
      Henan Cancer Hospital
    Dec 14, 2022

    Serum Neurofilament Light asMarker for Brain Injury in

    Recruiting
    • Neurotoxicity
      • Saint Louis, Missouri
        Washington University School of Medicine
      Oct 10, 2022

      Lymphomas, B-cell Lymphomas Trial in Houston (JV-213, Leukapheresis)

      Not yet recruiting
      • Lymphomas
      • B-cell Lymphomas
      • Houston, Texas
        The University of Texas M D Anderson Cancer Center
      Mar 6, 2023

      Chronic Lymphocytic Leukemia, B-Cell Chronic Lymphocytic Leukemia, Lymphoma, B-Cell Trial run by the National Cancer Institute

      Not yet recruiting
      • Chronic Lymphocytic Leukemia
      • +2 more
      • Anti-CD19 and anti-CD20 bicistronic CAR T- cells
      • +2 more
      • Bethesda, Maryland
        National Institutes of Health Clinical Center
      Apr 10, 2023

      Lymphoma, Leukemia, Plasma Cell Dyscrasia Trial in San Francisco (Web Application)

      Not yet recruiting
      • Lymphoma
      • +2 more
      • Web Application
      • San Francisco, California
        University of California, San Francisco
      Oct 4, 2022

      Sarcoma, Osteosarcoma, Neuroblastoma Trial run by the NCI (Anti-GD2-CAR engineered T cells, AP1903, Cyclophosphamide)

      Completed
      • Sarcoma
      • +3 more
      • Anti-GD2-CAR engineered T cells
      • +2 more
      • Bethesda, Maryland
        National Institutes of Health Clinical Center
      Jan 31, 2023